1 February 2025 in Circulation: Heart Failure
BACKGROUND: Despite previous histopathologic evidence for its presence, the role of myocardial inflammation in the development and progression of cardiac transthyretin amyloidosis (ATTR-CA) remains insufficiently understood. Thus, this study sought to characterize the prevalence and potential prognostic implications of myocardial inflammation in ATTR-CA. METHODS: A retrospective observational study including patients with ATTR-CA diagnosed by endomyocardial biopsy was conducted. Myocardial inflammation was diagnosed through a review of routine endomyocardial biopsy reports. Baseline characteristics were compared using the Mann-Whitney U test and the Pearson χ 2 test. Clinical outcomes were monitored via follow-up visits or telephone calls. Primary outcomes were all-cause death and a composite end point of all-cause death or heart failure hospitalization. Kaplan-Meier analyses, as well as univariable and age- and sex-adjusted multivariable Cox regression analyses, were used to assess differences in overall and composite end point-free survival between patients with ATTR-CA with and without myocardial inflammation. RESULTS: A total of 103 patients with ATTR-CA (100 wild type; 3 variant) were enrolled. Median follow-up was 18.2 (8.0–31.1) months. Myocardial inflammation was prevalent in 32% (n=33/103) of patients with ATTR-CA. Among evaluable patients with myocardial inflammation, 96% (n=26/27) and 31% (n=9/29) had elevated CD68 (clusters of differentiation 68)–positive macrophage and CD3 (clusters of differentiation 3)–positive T-cell counts, respectively. Overall survival ( P =0.017) and composite end point-free survival ( P =0.014) were significantly impaired in patients with ATTR-CA with myocardial inflammation (n=33) compared with those without (n=70). Statistical significance for both associations was sustained after adjustment for age and sex, yielding adjusted hazard ratios of 4.72 (95% CI, 1.33–16.71; P =0.016) and 2.30 (95% CI, 1.04–5.11; P =0.041) for all-cause death and the composite end point, respectively. CONCLUSIONS: Our findings affirm previous evidence that myocardial inflammation is present in approximately one-third of all patients with ATTR-CA. Moreover, we provide first data indicating that myocardial inflammation may be associated with a higher risk of death and heart failure hospitalizations in ATTR-CA.
16 July 2024 in Journal of the American Heart Association
Background: Results from ATTR‐ACT (Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy) indicate that tafamidis prolongs survival and reduces cardiovascular hospitalizations in cardiac transthyretin amyloidosis (ATTR‐CA). However, real‐world data supporting these findings are scarce. Thus, we sought to characterize the clinical outcome of patients with ATTR‐CA treated with tafamidis in a real‐world setting and assess the prognostic role of the New York Heart Association (NYHA) classification. Methods and Results: We conducted a retrospective observational study, enrolling a consecutive sample of patients with ATTR‐CA (wild‐type or variant) treated with tafamidis. Clinical outcome was tracked through follow‐up visits or phone calls. Primary outcomes were death and major adverse cardiac events (MACE), a composite end point of death and hospitalizations for acute cardiac decompensation, myocardial infarction, severe arrythmias, or stroke. Kaplan‐Meier analysis estimated overall and MACE‐free survival including NYHA subgroups (NYHA I/II versus NYHA III). One hundred sixty‐seven patients with ATTR‐CA (94.6% wild‐type) were enrolled and followed for a median of 539 [323–869] days. Median overall survival was not reached. Estimated 1‐year, 2‐year, and 5‐year overall survival among the whole cohort was 93.5%, 85.9%, and 70.2%, respectively. Overall survival was higher in the NYHA I/II subgroup ( P =0.002). Median MACE‐free survival time was 1082 (95% CI, 962–1202) days. MACE‐free survival was higher in the NYHA I/II subgroup ( P <0.001). With respective hazard ratios of 5.85 (95% CI, 1.48–23.18; P =0.012) and 3.95 (95% CI, 1.99–7.84; P <0.001), NYHA III was an independent predictor of death and MACE. Conclusions: Treatment of ATTR‐CA with tafamidis led to substantial improvements of clinical outcome. NYHA classification at treatment initiation is a reliable tool to provide patients with individualized prognostic information.
25 July 2024 in European Heart Journal - Imaging Methods and Practice
Left ventricular global longitudinal strain (LV-GLS) shows promise as a marker to detect early heart failure (HF). This study sought to (i) establish cardiac magnetic resonance imaging (CMR)–derived LV-GLS cut-offs to differentiate healthy from HF for both acquisition-based and post-processing techniques, (ii) assess agreement, and (iii) provide a method to convert LV-GLS between both techniques. A secondary analysis of a prospective study enrolling healthy subjects (n = 19) and HF patients (n = 56) was conducted. LV-GLS was measured using fast strain–encoded imaging (fSENC) and feature tracking (FT). Receiver operating characteristic (ROC) analyses were performed to derive and evaluate LV-GLS cut-offs discriminating between healthy, HF with mild deformation impairment (DI), and HF with severe DI. Linear regression and Bland–Altman analyses assessed agreement. Cut-offs discriminating between healthy and HF were identified at −19.3% and −15.1% for fSENC and FT, respectively. Cut-offs of −15.8% (fSENC) and −10.8% (FT) further distinguished mild from severe DI. No significant differences in area under ROC curve were identified between fSENC and FT. Bland–Altman analysis revealed a bias of −4.01%, 95% CI −4.42, −3.50 for FT, considering fSENC as reference. Linear regression suggested a factor of 0.76 to rescale fSENC-derived LV-GLS to FT. Using this factor on fSENC-derived cut-offs yielded rescaled FT LV-GLS cut-offs of −14.7% (healthy vs. HF) and −12% (mild vs. severe DI). LV-GLS distinguishes healthy from HF with high accuracy. Each measurement technique requires distinct cut-offs, but rescaling factors facilitate conversion. An FT-based LV-GLS ≥ −15% simplifies HF detection in clinical routine.
1 August 2026 in Circulation: Heart Failure
BACKGROUND: There is a growing consensus that screening for subclinical preheart failure (HF) may reduce the burden of symptomatic HF by allowing for timely preventive interventions. However, validated screening algorithms are currently lacking. The aim of this study was to evaluate a fully mobile telemedically supervised cardiac magnetic resonance, as a simple standardized, and ubiquitously applicable screening algorithm for subclinical pre-HF in rural and underresourced regions. METHODS: HERZCHECK was a cross-sectional cohort study conducted at 12 sites across rural and underresourced regions of Germany. Asymptomatic participants (40–69 years) with ≥1 cardiovascular risk factor—obesity, smoking, arterial hypertension, diabetes, hypercholesterolemia, or chronic kidney disease—were enrolled and underwent telemedically supervised contrast-free short cardiac magnetic resonance in mobile screening units. Subclinical pre-HF was diagnosed using a predefined cutoff of global longitudinal strain ≥−15%. A matched and entropy-balanced control cohort constructed from claims data was used to determine the time difference between detection of subclinical pre-HF in HERZCHECK and the first symptom-based diagnosis of HF within the standard of care. RESULTS: Between June 2021 and April 2023, 4666 participants were enrolled in the study, of which 4509 participants were included in the final analysis. The prevalence of subclinical pre-HF in the studied at-risk population was 22.7% (95% CI, 21.5%–23.9%). Global longitudinal strain-based screening identified subclinical pre-HF 6.7 years before the average onset of symptomatic HF within the standard of care (n=8420). CONCLUSIONS: Subclinical pre-HF affects approximately one-fourth of the at-risk population in rural and underresourced regions. The HERZCHECK approach identifies patients suitable for targeted preventive interventions ≈7 years earlier than the standard of care. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05122793.
21 July 2025 in ESC Heart Failure
Aims: Myocardial inflammation is increasingly recognized for its association with impaired clinical outcomes in cardiac amyloidosis but a trend towards less invasive diagnosis impedes its detection. The aim of this study was to assess magnetocardiography (MCG) as a potential non-invasive method to diagnose myocardial inflammation in patients with cardiac amyloidosis. Methods and results: This retrospective proof-of-concept study included 27 patients with cardiac amyloidosis who had undergone MCG and endomyocardial biopsy as part of their diagnostic workup. Immunohistopathological evaluation identified myocardial inflammation in 10 patients (37.0%). Patients with myocardial inflammation had significantly higher magnetocardiography vector (VMCG) values than those without (0.093 [IQR 0.058–0.183] vs. 0.052 [IQR 0.039–0.073]; P = 0.01). With an area under the curve of 0.785 (95% CI 0.600–0.970; P < 0.01), VMCG had significant diagnostic value for myocardial inflammation in cardiac amyloidosis when tested against a non-informative random classifier in receiver operating characteristic analysis. Youden's index identified VMCG ≥0.078 as the optimal cut-off to discriminate between patients with and without myocardial inflammation, yielding a sensitivity of 60.0%, a specificity of 88.2%, a positive predictive value of 75.0% and a negative predictive value of 78.9%. Conclusions: This proof-of-concept study provides initial evidence for the potential of MCG as a non-invasive method to identify myocardial inflammation in patients with cardiac amyloidosis. These findings require validation in larger prospective studies but could substantially contribute to the optimization of personalized management in patients diagnosed with cardiac amyloidosis via non-invasive pathways in the future.
6 January 2026 in Journal of the American Heart Association
Background: Bio‐ADM (bioactive adrenomedullin) is a vasoactive peptide hormone that predicts clinical outcomes in heart failure—the main driver of adverse outcomes in cardiac amyloidosis (CA). This prospective observational study sought to assess the prognostic role of bio‐ADM in CA. Methods: Patients with CA were enrolled from amyloid centers in Germany (observation cohort), Japan, and the United States (combined validation cohort). Bio‐ADM was quantified using the sphingotest bio‐ADM assay. Associations of bio‐ADM with all‐cause death and major adverse cardiovascular events over 2 years were assessed using Kaplan–Meier and Cox regression analyses. Likelihood ratio chi‐square tests for nested models evaluated whether adding bio‐ADM improves validated prognostic staging systems. Results: In both the German observation cohort (n=86) and the combined validation cohort from Japan and the United States (n=124), elevated bio‐ADM (>29 pg/mL) was associated with more frequent all‐cause death and major adverse cardiovascular events. Bio‐ADM remained independently associated with impaired overall ( P <0.001) and major adverse cardiovascular events‐free survival ( P 29 pg/mL) significantly improved the prognostic accuracy of the National Amyloidosis Centre (C‐index 0.674 to 0.787; P =0.002) and MayoATTR (C‐index 0.662 to 0.757; P <0.001) staging systems for cardiac transthyretin amyloidosis. Adding bio‐ADM to staging systems for cardiac immunoglobulin light chain amyloidosis yielded no significant changes. Conclusions: Bio‐ADM is a promising prognostic biomarker, especially in cardiac transthyretin amyloidosis, where it improved risk stratification when added to established staging systems. Further research is needed to clarify its role as part of staging systems for cardiac immunoglobulin light chain amyloidosis.